At Ceria Therapeutics, we are developing a pipeline of first-in-class therapeutic products that address acute, severe inflammatory conditions based on a novel nanoparticle platform for RNA delivery.
01
A Breakthrough in RNA delivery
Our proprietary platform uses cerium oxide nanoparticles (CNPs) to induce high-yield cellular delivery of therapeutic compounds. CNPs are inexpensive, non-toxic, and very efficient cellular delivery of RNA, DNA, small molecules, or biologics to cells throughout the body.
02
Targeting miRNA-146a: A Key Regulator of Inflammation
Micro-Ribonucleic Acids (miRNAs) comprise a class of critical genetic regulatory molecules. miRNA-146a is the key regulator of the acute inflammatory pathway. Increasing miRNA-146a results in rapid and durable suppression of pro-inflammatory cytokines and treatment of various inflammatory conditions.
03
How Our Technology Works
Our first-in-class products incorporate CNP-miR146a, a miRNA-146a conjugated to CNP. This novel molecule allows for highly efficient delivery of miRNA-146a to suppress the acute inflammatory pathway. By delivering CNP-miR146a directly to the site of inflammation, we restore balance to the inflammatory response and halt disease progression.
04
Mechanism of Action
A – High-yield conjugation results in ~100 copies/CNP
B – CNPs induce high-efficiency endocytosis preferentially by macrophages and also induce endosomal escape to release CNPmiR146a into the cytosol of cells
C – Endogenous cytosolic esterases release the miR-146a payload
miR-146a is a non-coding microRNA that specifically binds to the 3’-ends of mRNA transcripts for IRAK1 and TRAF6. When bound, the miR-146a/mRNA hybrid is trafficked to the RNA degradation complex for enzymatic cleavage to single base monomers.
A – In response to tissue injury (chemical exposure, pathogen exposure, toxin exposure, impact injury) signals, expression of TRAF6 and IRAK1 is rapidly upregulated, both of which activate NF-kB resulting in increased expression and release of pro-inflammatory cytokines.
B – miR-146a reduces TRAF6 and IRAK1 expression resulting in reduced NF-kB activation and subsequently reduced pro-inflammatory cytokine release.
05
Safety and Efficacy
We are committed to proving the safety and efficacy of drug products containing CNP-miR146a. Several properties of this molecule strongly support the potential clinical safe and efficacious use of our pipeline.
- Potent Effect: In several models of acute inflammation, CNP-miRNA146a rapidly and durably blocks the signaling pathway, reduces inflammation, and resolves disease.
- Naturally Inspired: miRNA-146a is naturally produced in the body that regulates pro-inflammatory cytokine release, while cerium is an abundant and non-toxic environmental element.
- Localized Delivery: Our drug products containing CNP-miRNA146a are administered in small, localized doses that do not enter systemic circulation thus minimizing systemic exposure and potential side effects.
- Low Metabolism Risk: CNP-miR146a is not metabolized and is designed for minimal metabolic impact, ensuring a safe therapeutic profile with minimal side effects.
CONTACT US
OUR ADDRESS
Ceria Therapeutics, Inc
1230 N Cherry Ave, BSRL 329
Tucson, AZ 85721